Breakthrough Immunotherapies And Aging Trends Will Revitalize Global Oncology
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
20 Jun 25
Updated
14 Jul 25
AnalystHighTarget's Fair Value
HK$141.33
13.8% overvalued intrinsic discount14 Jul
HK$160.80
1Y
263.0%7D
5.7%